Latest Period
Q1 2026
Security Snapshot
Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) Institutional Ownership
CUSIP: 45782T105
13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026
Institutions Reporting
77
Shares (Excl. Options)
5,343,033
Price
$1.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- INMB on Nasdaq
- Shares outstanding
- 27,969,231
- Price per share
- $1.33
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 5,343,033
- Total reported value
- $6,047,600
- % of total 13F portfolios
- 0%
- Share change
- +297,592
- Value change
- +$291,689
- Number of holders
- 77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- INMB - Inmune Bio, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 45782T105.
- 77 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 73 to 77 between Q4 2025 and Q1 2026.
- Reported value moved from $7,930,834 to $6,047,600.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 77 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 45782T105?
CUSIP 45782T105 identifies INMB - Inmune Bio, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45782T105:
Significant Owners of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 5.2% | $3,359,664 | 1,454,400 | Highbridge Capital Management, LLC | 30 Jun 2025 | |||
| CVI Investments, Inc. | 4.9% | -10% | $3,225,404 | -$239,596 | 1,396,279 | -6.9% | CVI Investments, Inc. | 30 Jun 2025 |
| Praetorian PR LLC | 3.4% | -54% | $2,127,972 | -$1,700,160 | 921,200 | -44% | Kupperman Harris | 30 Jun 2025 |
As of 31 Mar 2026, 77 institutional investors reported holding 5,343,033 shares of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB). This represents 19% of the company’s total 27,969,231 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) together control 18% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4.3% | 1,194,112 | -1.5% | 0% | $1,349,347 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 687,015 | 0% | 0% | $776,327 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 494,969 | +12% | 0% | $559,464 |
| STATE STREET CORP | 1% | 290,879 | -16% | 0% | $328,693 |
| AQR CAPITAL MANAGEMENT LLC | 0.97% | 270,317 | +1217% | 0% | $305,458 |
| UBS Group AG | 0.91% | 253,340 | +317% | 0% | $286,274 |
| GOLDMAN SACHS GROUP INC | 0.83% | 231,586 | +310% | 0% | $261,692 |
| RAYMOND JAMES FINANCIAL INC | 0.73% | 203,245 | -3.5% | 0% | $229,667 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.7% | 194,391 | -23% | 0% | $219,662 |
| NORTHERN TRUST CORP | 0.66% | 184,225 | +4.9% | 0% | $208,174 |
| Dauntless Investment Group, LLC | 0.66% | 183,476 | -40% | 0.58% | $207,328 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.46% | 129,218 | 0% | 0% | $146,016 |
| VANGUARD FIDUCIARY TRUST CO | 0.44% | 123,184 | 0% | 0% | $139,198 |
| Westside Investment Management, Inc. | 0.39% | 108,300 | -0.6% | 0.02% | $122,383 |
| Bank of New York Mellon Corp | 0.19% | 53,628 | -8.4% | 0% | $60,599 |
| JANE STREET GROUP, LLC | 0.18% | 50,944 | +122% | 0% | $57,566 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 50,252 | 0% | 0% | $56,785 |
| Laird Norton Wetherby Trust Company, LLC | 0.18% | 50,000 | +11% | 0% | $56,500 |
| MORGAN STANLEY | 0.16% | 44,611 | -64% | 0% | $50,411 |
| Focus Partners Advisor Solutions, LLC | 0.15% | 43,025 | +4.7% | 0% | $48,618 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.14% | 40,120 | +6.1% | 0% | $45,336 |
| JPMORGAN CHASE & CO | 0.12% | 33,245 | -20% | 0% | $37,899 |
| Quadrature Capital Ltd | 0.12% | 32,362 | +91% | 0% | $36,569 |
| XTX Topco Ltd | 0.11% | 30,306 | -56% | 0% | $34,246 |
| IEQ CAPITAL, LLC | 0.09% | 24,563 | 0% | $27,756 |
Institutional Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,343,033 | $6,047,600 | +$291,689 | $1.13 | 77 |
| 2025 Q4 | 5,083,640 | $7,930,834 | +$653,755 | $1.56 | 73 |
| 2025 Q3 | 4,655,922 | $9,636,676 | -$1,934,721 | $2.07 | 73 |
| 2025 Q2 | 5,623,690 | $12,725,267 | -$10,010,248 | $2.31 | 78 |
| 2025 Q1 | 6,162,475 | $48,114,521 | -$163,536 | $7.81 | 81 |
| 2024 Q4 | 6,324,914 | $29,538,643 | +$2,163,001 | $4.67 | 72 |
| 2024 Q3 | 5,352,153 | $28,834,750 | +$6,030,346 | $5.39 | 65 |
| 2024 Q2 | 4,566,933 | $40,279,815 | +$15,412,868 | $8.82 | 56 |
| 2024 Q1 | 2,738,821 | $32,179,382 | +$5,308,168 | $11.75 | 50 |
| 2023 Q4 | 2,292,004 | $25,807,938 | +$1,854,241 | $11.26 | 47 |
| 2023 Q3 | 2,133,529 | $14,477,326 | -$5,887,298 | $6.77 | 36 |
| 2023 Q2 | 2,186,070 | $24,850,986 | +$8,529,775 | $9.08 | 32 |
| 2023 Q1 | 1,804,387 | $11,657,371 | +$1,101,433 | $6.46 | 33 |
| 2022 Q4 | 1,645,407 | $10,430,707 | -$728,047 | $6.34 | 32 |
| 2022 Q3 | 1,912,551 | $11,855,780 | -$744,186 | $6.20 | 32 |
| 2022 Q2 | 2,010,894 | $17,633,536 | -$2,412,787 | $8.84 | 34 |
| 2022 Q1 | 2,294,234 | $19,315,368 | -$2,106,118 | $8.42 | 32 |
| 2021 Q4 | 2,484,556 | $25,343,080 | +$4,757,601 | $10.20 | 42 |
| 2021 Q3 | 1,942,445 | $37,703,608 | +$4,889,864 | $19.42 | 40 |
| 2021 Q2 | 1,710,752 | $30,053,028 | +$8,038,213 | $17.57 | 39 |
| 2021 Q1 | 1,305,763 | $15,492,692 | +$5,444,483 | $11.88 | 32 |
| 2020 Q4 | 793,136 | $13,655,776 | +$1,189,170 | $17.21 | 25 |
| 2020 Q3 | 992,741 | $10,252,248 | +$6,463,618 | $10.30 | 27 |
| 2020 Q2 | 358,561 | $1,881,000 | +$104,639 | $5.17 | 11 |
| 2020 Q1 | 342,213 | $1,139,000 | +$200,616 | $3.32 | 9 |
| 2019 Q4 | 282,367 | $1,637,000 | +$40,401 | $5.80 | 9 |
| 2019 Q3 | 274,538 | $1,620,000 | +$1,390,869 | $5.90 | 9 |
| 2019 Q2 | 38,466 | $373,000 | -$43,981 | $9.72 | 7 |
| 2019 Q1 | 45,117 | $352,000 | +$352,000 | $7.44 | 5 |